Pharmesis International Ltd. (SGX: BFK)
Singapore
· Delayed Price · Currency is SGD 0.625
0.00 (0.00%)
Nov 20, 2024, 9:00 AM SGT
Pharmesis International Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 41.81 | 45.64 | 50.37 | 52.77 | 47.11 | 37.2 | Upgrade
|
| Revenue Growth (YoY) | -29.49% | -9.40% | -4.55% | 12.01% | 26.63% | -42.17% | Upgrade
|
| Cost of Revenue | 29.34 | 29.62 | 26.36 | 27.77 | 23.25 | 18.18 | Upgrade
|
| Gross Profit | 12.47 | 16.02 | 24.01 | 25 | 23.86 | 19.02 | Upgrade
|
| Selling, General & Admin | 22.3 | 23.61 | 26.54 | 23.94 | 28.18 | 29.5 | Upgrade
|
| Operating Expenses | 22.37 | 23.61 | 26.54 | 23.94 | 28.18 | 29.5 | Upgrade
|
| Operating Income | -9.91 | -7.6 | -2.53 | 1.06 | -4.32 | -10.48 | Upgrade
|
| Interest Expense | -0.75 | -0.87 | -0.94 | -1.04 | -0.92 | -0.94 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.02 | 0.03 | 0.03 | 0.04 | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.05 | 0.05 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 3.54 | 3.54 | 0.28 | 2.06 | 0.55 | 0.08 | Upgrade
|
| EBT Excluding Unusual Items | -7.05 | -4.86 | -3.16 | 2.12 | -4.65 | -11.27 | Upgrade
|
| Asset Writedown | - | - | - | - | -1.34 | -7.06 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.16 | -1.2 | Upgrade
|
| Pretax Income | -7.05 | -4.86 | -3.16 | 2.12 | -5.84 | -19.53 | Upgrade
|
| Income Tax Expense | 1.14 | 0.05 | 0.02 | 0.15 | 0.01 | -0.28 | Upgrade
|
| Earnings From Continuing Operations | -8.19 | -4.9 | -3.18 | 1.97 | -5.85 | -19.26 | Upgrade
|
| Minority Interest in Earnings | 0.79 | -0.05 | -0.38 | -0.8 | 0.02 | 1.59 | Upgrade
|
| Net Income | -7.4 | -4.96 | -3.56 | 1.17 | -5.83 | -17.67 | Upgrade
|
| Net Income to Common | -7.4 | -4.96 | -3.56 | 1.17 | -5.83 | -17.67 | Upgrade
|
| Shares Outstanding (Basic) | 28 | 26 | 23 | 23 | 23 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 26 | 23 | 23 | 23 | 23 | Upgrade
|
| Shares Change (YoY) | 15.38% | 14.85% | - | - | - | - | Upgrade
|
| EPS (Basic) | -0.27 | -0.19 | -0.15 | 0.05 | -0.25 | -0.77 | Upgrade
|
| EPS (Diluted) | -0.27 | -0.19 | -0.15 | 0.05 | -0.25 | -0.77 | Upgrade
|
| Free Cash Flow | -7.44 | -12.17 | 6.33 | -0.93 | 0.77 | -4.06 | Upgrade
|
| Free Cash Flow Per Share | -0.27 | -0.46 | 0.28 | -0.04 | 0.03 | -0.18 | Upgrade
|
| Gross Margin | 29.82% | 35.09% | 47.67% | 47.38% | 50.65% | 51.13% | Upgrade
|
| Operating Margin | -23.69% | -16.64% | -5.02% | 2.01% | -9.17% | -28.16% | Upgrade
|
| Profit Margin | -17.69% | -10.86% | -7.07% | 2.22% | -12.37% | -47.50% | Upgrade
|
| Free Cash Flow Margin | -17.80% | -26.66% | 12.56% | -1.76% | 1.64% | -10.92% | Upgrade
|
| EBITDA | -8.72 | -6.42 | -1.19 | 2.33 | -3 | -9.06 | Upgrade
|
| EBITDA Margin | -20.85% | -14.06% | -2.36% | 4.42% | -6.37% | -24.34% | Upgrade
|
| D&A For EBITDA | 1.19 | 1.18 | 1.34 | 1.27 | 1.32 | 1.42 | Upgrade
|
| EBIT | -9.91 | -7.6 | -2.53 | 1.06 | -4.32 | -10.48 | Upgrade
|
| EBIT Margin | -23.69% | -16.64% | -5.02% | 2.01% | -9.17% | -28.16% | Upgrade
|
| Effective Tax Rate | - | - | - | 7.04% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.